Table 3.
Registered phase I/II clinical trials in the treatment of UC by MSCs.
| ClinicalTrials.gov Identifier | Study | Number of Patients | Type of Stem Cell |
|---|---|---|---|
| NCT03299413 | Hanan Jafar in University of Jordan | 20 | WJSCs |
| NCT02874365 | Emmanuel Mas in Toulouse University Hospital, France | 120 | ISCs |
| NCT03115749 | Guillaume Pineton in Montpellier University Hospital | 60 | NA |
| NCT03369353 | Leslie Kean in Seattle Children’s Hospital, USA | 625 | HSCs |
| NCT03609905 | Peng Yan in Liaocheng People’s Hospital, China | 50 | AdSCs |
| NCT 01914887 | In Instituto de Investigaci on Hospital Universitario La Paz, Bolivia | 8 | AdSCs (60 × 106 cells/kg, endoscopic injection in colonic submucosa) |
| NCT 01221428 | In Qingdao University, China | NA | UCSCs (2 × 107 cells/kg, 1 week later 1 × 107 cells/kg, IV) |
| NCT 02442037 | Affiliated Hospital to Academy of Military Medical Sciences, China | 30 | UCSCs (1 × 106 cells/kg, IV, 3 weekly) |
| NCT 02150551 | Children’s National Medical Center, Washington, USA | NA | BMSCs (1 × 106 cells/kg, IV, 8 weekly) |
MSCs: Mesenchymal stem cells. WJSCs: Wharton Jelly stem cells. ISCs: Intestinal stem cells. HSCs: Hematopoietic stem cells. AdSCs: Adipose-derived stem cells. UCSCs: Umbilical cord-derived stem cells. BMSCs: Bone marrow-derived stem cells. NA: Not available. IV: Intravenously.